🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 01/06/2022 | 275,33 | 275,56 | 266,18 | 269,41 | +0,28% | 3,41% | 1.377.600 |
| 31/05/2022 | 274,03 | 276,00 | 266,47 | 268,65 | -1,86% | 3,48% | 3.878.600 |
| 27/05/2022 | 271,15 | 273,86 | 268,93 | 273,73 | +1,51% | 1,82% | 1.479.100 |
| 26/05/2022 | 270,84 | 274,17 | 268,87 | 269,65 | -0,44% | 1,96% | 1.376.600 |
| 25/05/2022 | 269,70 | 273,19 | 267,82 | 270,84 | +0,88% | 1,99% | 1.880.700 |
| 24/05/2022 | 265,51 | 270,98 | 263,78 | 268,48 | +0,05% | 2,71% | 1.622.100 |
| 23/05/2022 | 260,05 | 270,28 | 259,19 | 268,35 | +3,77% | 4,26% | 1.674.000 |
| 20/05/2022 | 256,61 | 259,10 | 252,51 | 258,59 | +1,23% | 2,57% | 1.552.300 |
| 19/05/2022 | 252,55 | 257,15 | 250,38 | 255,45 | +1,23% | 2,68% | 1.448.800 |
| 18/05/2022 | 260,59 | 262,08 | 251,41 | 252,35 | -3,62% | 4,09% | 1.397.000 |
| 17/05/2022 | 255,82 | 262,95 | 254,67 | 261,84 | +3,02% | 3,24% | 1.566.800 |
| 16/05/2022 | 245,85 | 254,71 | 244,61 | 254,17 | +3,02% | 4,11% | 1.558.200 |
| 13/05/2022 | 241,22 | 247,54 | 240,25 | 246,72 | +2,44% | 3,02% | 1.366.600 |
| 12/05/2022 | 236,55 | 241,05 | 233,62 | 240,85 | +2,51% | 3,14% | 1.475.400 |
| 11/05/2022 | 237,85 | 241,75 | 233,01 | 234,96 | -2,17% | 3,67% | 1.905.900 |
| 10/05/2022 | 239,58 | 244,10 | 237,41 | 240,16 | +2,19% | 2,79% | 2.041.500 |
| 09/05/2022 | 251,00 | 251,00 | 234,40 | 235,02 | -7,45% | 6,61% | 3.148.800 |
| 06/05/2022 | 256,32 | 261,68 | 252,69 | 253,93 | -4,67% | 3,51% | 2.268.500 |
| 05/05/2022 | 271,69 | 273,59 | 264,59 | 266,37 | -2,68% | 3,31% | 1.556.900 |
| 04/05/2022 | 269,34 | 275,26 | 266,24 | 273,70 | +1,71% | 3,35% | 1.353.400 |
| 03/05/2022 | 266,55 | 271,25 | 265,58 | 269,11 | +2,73% | 2,13% | 1.363.500 |
| 02/05/2022 | 264,15 | 266,19 | 254,09 | 261,96 | -4,12% | 4,58% | 3.748.700 |
| 29/04/2022 | 275,00 | 279,71 | 272,63 | 273,22 | +1,70% | 2,57% | 2.871.500 |
| 28/04/2022 | 268,57 | 269,30 | 262,22 | 268,64 | +0,52% | 2,64% | 1.620.700 |
| 27/04/2022 | 267,33 | 269,39 | 264,81 | 267,25 | -0,16% | 1,71% | 1.240.000 |
| 26/04/2022 | 271,07 | 272,23 | 267,39 | 267,69 | -1,47% | 1,79% | 1.446.500 |
| 25/04/2022 | 270,00 | 272,50 | 265,87 | 271,68 | +0,47% | 2,46% | 1.688.700 |
| 22/04/2022 | 280,58 | 281,84 | 270,19 | 270,42 | -4,01% | 4,15% | 1.774.300 |
| 21/04/2022 | 286,00 | 286,80 | 281,45 | 281,71 | -1,26% | 1,87% | 1.118.600 |
| 20/04/2022 | 284,34 | 286,88 | 282,77 | 285,30 | +0,98% | 1,45% | 1.115.800 |